Anti-NRP1A antibodies and their use in treating eyes or eye diseases
By targeting the A domain of Nrp1, using anti-Nrp1A antibodies or antigen-binding fragments, the penetration of blood retinal barrier induced by Sema3A and VEGF-A is solved, and the problems of vascular regeneration and pathological neoangiogenesis in diabetic retinopathy are achieved, effectively improving retinal vascular regeneration and visual protection.
CN114423788BActive Publication Date: 2025-04-01BOEHRINGER INGELHEIM INT GMBH
32 Cites 0 Cited by
Patent Information
- Application Number
- CN202080066882.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-09
- Filing Date
- 2020-09-24
- Publication Date
- 2025-04-01
- Estimated Expiration
- 2040-09-24
AI Technical Summary
Technical Problem
The prior art is difficult to effectively solve the fundamental ischemia problem that drives pathological vascular growth in the treatment of diabetic retinopathy, and the standard treatment methods for proliferative retinopathy are inefficient, resulting in a gradual loss of vision in patients.
Method used
Targeting the A domain of Nrp1, using anti-Nrp1A antibodies or antigen-binding fragments thereof, promote retinal vascular regeneration and reduce pathological neoangiogenesis by inhibiting Sema3A and VEGF-A induced permeability of blood retinal barriers.
Benefits of technology
Effectively improve retinal vascular regeneration, reduce retinal pathological neovascularization, reduce blood retinal barrier damage induced by Sema3A and VEGF-A, and delay or prevent vision loss.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to antibodies and fragments thereof that target the A domain of neuropilin-1 (Nrp1A). More specifically, the present invention discloses anti-Nrp1A antibodies and methods of use for treating various diseases or conditions.
Need to check novelty before this filing date? Find Prior Art